H.C. Wainwright analyst Emily Bodnar has maintained their neutral stance on GERN stock, giving a Hold rating on November 28.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on the recent data presentations at the ASH 2025 conference, where Geron showcased incremental updates on imetelstat’s clinical trials. The data highlighted a significant correlation between cytopenias and clinical response in patients with lower-risk myelodysplastic syndromes (LR-MDS), suggesting that reductions in platelets and neutrophils might be indicative of treatment efficacy rather than adverse effects. This correlation was observed in both the rise of hemoglobin levels and the durability of red blood cell transfusion independence, indicating potential benefits of imetelstat.
However, despite these promising findings, the improvements in overall survival and progression-free survival were modest, with only slight advantages over placebo. Additionally, the data presented were incremental and did not introduce groundbreaking changes to the existing understanding of imetelstat’s efficacy. These factors contribute to a cautious outlook, leading to a Hold rating as the company continues to gather more comprehensive data to support imetelstat’s long-term benefits.
In another report released on November 28, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.